Skin type I to IV on the Fitzpatrick Skin Type Scale
Diagnosis of non-invasive (stage 0) or invasive (stage 1, 2 and 3A) breast adenocarcinoma.
Treatment with neoadjuvant (preoperative) or adjuvant (postoperative) chemotherapy: anthracycline and taxane containing (paclitaxel or docetaxel) chemotherapy regimen.
Diagnosed with CIA grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE)
Have no documented or observable psychiatric or neurological disorders that might interfere with study participation (e.g., dementia or psychosis).
You may not be if
Metastatic disease
Severe or unstable cardio- respiratory or musculoskeletal disease
Pregnancy
Presence of cognitive impairment that might impact study outcomes
Previously (before start of chemotherapy) diagnosed with a hair loss condition
Take any of the following medications for 6 months prior to initiation of the study: minoxidil, finasteride (or any other 5α-reductase inhibitor medications), medications with anti-androgenic properties (e.g. cyproterone, spironolactone, ketoconazole, flutamide and bicalutamide)n medications that can potentially cause hypertrichosis (ciclosporin, diazoxide, phenytoin and psoralens), and oral glucocorticoids
Clareo Health | PBMT for the Management of CIA ( HAIRLASER )
